✦ LIBER ✦

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

✍ Scribed by Hester van Cruijsen; Emile E. Voest; Cornelis J.A. Punt; Klaas Hoekman; Petronella O. Witteveen; Martijn R. Meijerink; Thomas A. Puchalski; Jane Robertson; Owain Saunders; Juliane M. Jürgensmeier; Carla M.L. van Herpen; Giuseppe Giaccone

Book ID: 116430259
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 392 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2009.12.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I open-label study of cediranib, a

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

✍ Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Vesile Schneider, Dirk Strum 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 379 KB

1230 Cediranib (an oral, highly potent V

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

✍ T. Trarbach; J. Drevs; D. Strumberg; T.C. Gauler; V. Schneider; W.E. Eberhardt; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

394 POSTER Final results of a Phase I st

394 POSTER Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

✍ H. Murakami; N. Yamamoto; N. Boku; K. Yamazaki; N. Yamamoto; Y. Yamada; K. Yamad 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Phase I, dose escalation and pharmacokin

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

Phase I study of the multidrug resistanc

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

✍ Lyly H. Lê; Malcolm J. Moore; Lillian L. Siu; Amit M. Oza; Martha MacLean; Bryn 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 285 KB

Phase I study of olaparib in combination

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

✍ Del Conte, G; Sessa, C; von Moos, R; Viganò, L; Digena, T; Locatelli, A; Gallera 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 299 KB